Impact of topiramate migraine prophylaxis on workplace productivity: Results from two US randomized, double-blind, placebo-controlled, multicenter trials

Jennifer H. Lofland, Joshua J. Gagne, Laura T. Pizzi, Marcia Rupnow, Stephen D. Silberstein

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

OBJECTIVE: We conducted this study to determine whether topiramate at 100 mg/d for the treatment of migraine headache is associated with improved productivity in the workplace. METHODS: Results were derived from two randomized, double-blind, placebo-controlled trials among migraineurs. The number of hours of absenteeism (A), presenteeism (P), and total lost productivity (TLP) (A + P) were calculated. Results were not adjusted for multiplicity. RESULTS: A total of 325 (162 in the topiramate group and 163 in the placebo group) of 449 subjects were included. Per person mean monthly A rate was only significantly less for individuals within the topiramate group (1.0 hours per person) versus those in the placebo group (1.5 hours per person) for month 3 (P < 0.05). Per person mean P and TLP rates were significantly lower for individuals in the topiramate group versus those in the placebo group for months 1 through 5 (P < 0.05). CONCLUSIONS: Findings suggest that topiramate, compared with placebo, is associated with decreased workplace presenteeism and TLP.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalJournal of occupational and environmental medicine
Volume49
Issue number3
DOIs
StatePublished - Mar 2007

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Impact of topiramate migraine prophylaxis on workplace productivity: Results from two US randomized, double-blind, placebo-controlled, multicenter trials'. Together they form a unique fingerprint.

Cite this